High-Dimensional Single-Cell Proteomic Analysis Reveals Therapeutic Vulnerabilities In Relapsed/Refractory Aml By Concomitant Analysis Of Cell Surface Antigens, Signaling Pathways And Anti-Apoptotic Proteins

Background: The heterogeneous and adaptive nature of AML-associated genomic and proteomic landscape may account for disease relapse and poor prognosis, as therapy-associated selective pressure drives the emergence and expansion of AML clones with features different from those detected at diagnosis. The evolving focus is on single-cell analytical tools to fully capture the pathobiological heterogeneity of AML. We leveraged CyTOF to interrogate the proteomic heterogeneity in patients with R/R AML, which could potentially permit the design of rational combinatorial therapeutic approaches targeting vulnerabilities in these cells..